Revelyx获数千万美元A轮投资，重组A型肉毒液体制剂在海外开展II期临床｜36氪首发｜36氪首发

Group 1 - Revelyx Bio Inc. has recently completed a multi-million dollar Series A financing round led by NRL Capital, with funds aimed at advancing clinical research and commercial expansion of its products globally [1] - The company, established in Delaware in 2025, is a NewCo incubated by NRL Capital and two other international investment institutions, focusing on a core pipeline product, a liquid formulation of botulinum toxin type A (003), which is currently undergoing Phase II clinical trials in Australia for glabellar lines [1] - Revelyx holds exclusive licensing rights for 003 in overseas markets outside of mainland China, Hong Kong, and Macau, with plans to submit for Phase III clinical trials in 2026 [1] Group 2 - The NewCo model allows Chinese pharmaceutical companies to license out their product pipelines to international entities, receiving cash and equity compensation, while aiming for eventual public listing and commercialization partnerships in overseas markets [2] - NRL Capital's medical team emphasizes that the NewCo model helps mitigate risks associated with expanding original Chinese innovations into consumer healthcare, while focusing resources on core products with international competitive advantages [2] - The production of botulinum toxin has evolved, with recent innovations allowing for recombinant products that offer improved safety, reliability, and purity, aligning with the trend of shifting from extraction to recombinant technology in biopharmaceuticals [3] Group 3 - The technology used by Revelyx's partner has successfully expressed stable, high-purity, and highly active botulinum toxin core proteins in E. coli, with the first-generation product completing Phase III trials, demonstrating safety and immunogenicity [3] - The 003 product represents an upgraded formulation from traditional freeze-dried to liquid pre-filled syringes, enhancing convenience and usability [3] - NRL Capital's medical team believes that the investment in the recombinant botulinum toxin liquid formulation will provide a superior, safe, and reliable experience for global users, addressing issues of resistance and ensuring precise effects [3]